A cost-consequence analysis of the preferential use of secukinumab versus adalimumab for the treatment of psoriatic arthritis

Jiménez-Morales, Alberto; Cáliz, Rafael; Aceituno, Susana; Prades, Miriam; Blanch, Carles.
Reumatol. clín. (Barc.) ; 17(9): 536-542, Nov. 2021. tab, ilus, graf
Artículo en Inglés | IBECS (España) | ID: ibc-213360

Documentos relacionados

  1. A cost-consequence analysis of the preferential use of secukinumab versus adalimumab for the treatment of psoriatic arthritis.
  2. [Revised version of the statement by the DGRh on biosimilars-update 2017].
  3. Adalimumab-Adbm: The First Interchangeable Biosimilar for the Treatment of Inflammatory Diseases.
  4. Efficacy and safety of adalimumab in pediatric patients with Crohn's disease: A systematic review and meta-analysis.
  5. Pharmacokinetic and clinical monitoring through posologic changes in adalimumab intensification regimen from 40 mg every week to 80 mg every other week.
  6. AURIEL-PsO: a randomized, double-blind phase III equivalence trial to demonstrate the clinical similarity of the proposed biosimilar MSB11022 to reference adalimumab in patients with moderate-to-severe chronic plaque-type psoriasis.
  7. SPOSAB ABP 501: A Sicilian Prospective Observational Study of Patients with Inflammatory Bowel Disease Treated with Adalimumab Biosimilar ABP 501.
  8. Switching between reference adalimumab and biosimilars in chronic immune-mediated inflammatory diseases: A systematic literature review.
  9. Budget impact analysis and treatment availability with biosimilar TNF inhibitors in rheumatic diseases in Poland: real-world evidence using a nationwide database.
  10. Proactive therapeutic drug monitoring of adalimumab for pediatric Crohn's disease patients: A cost-effectiveness analysis.